Pathogenic Insights and Search for Biomarkers in RFC1-ataxia/CANVAS

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorCatholic University of the Sacred Heart

About this trial

CANVAS (Cerebellar Ataxia, Neuropathy, Vestibular Areflexia Syndrome), also referred to as RFC1-ataxia, is a recently molecularly characterized neurodegenerative disorder caused by a biallelic expansion of an AAGGG pentanucleotide repeat in intron 2 of the Replication Factor C subunit 1 (RFC1) gene.

This adult-onset condition presents with a variable combination of cerebellar ataxia, peripheral neuropathy, and vestibular dysfunction. Currently, limited data are available regarding its natural history and the molecular mechanisms by which this dynamic mutation leads to neurodegeneration of selective neuronal populations.

Given that recent literature identifies RFC1/CANVAS as a relatively common genetic cause of late-onset ataxia, elucidation of its underlying pathogenic mechanisms may offer insights into the molecular pathways implicated in more prevalent late-onset neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease.

Eligibility criteria

Qualifiers

Molecular diagnosis of RFC1-ataxia

age >18 years and <80 years

ability to sign informed consent

Disqualifiers

Diagnosis of other degenerative and/or non-degenerative neurological diseases

Not signed informed consent

Trial design

Treatments tested in this trial

  • Assessment of markers of oxidative stress in peripheral blood samples

Treatment groups

50 Participants
are divided into 2 treatment groups